Trials / Unknown
UnknownNCT04917250
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Gemcitabine, Pegaspargase, Etoposide, and Dexamethasone (GPED) for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Beijing Tongren Hospital · Academic / Other
- Sex
- All
- Age
- 16 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of GPED (gemcitabine, pegaspargase, etoposide, and dexamethasone) regimen in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine | 1000mg/㎡，d1,4 ivdrip |
| DRUG | Pegaspargase | 2500IU/㎡, maximum dose less than 3750IU |
| DRUG | Etoposide | 100mg/㎡，d1-3 ivdrip |
| DRUG | Dexamethasone | 20mg/d d1-4 ivdrip |
Timeline
- Start date
- 2020-03-20
- Primary completion
- 2021-06-30
- Completion
- 2021-08-31
- First posted
- 2021-06-08
- Last updated
- 2021-06-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04917250. Inclusion in this directory is not an endorsement.